Market Research Logo

Non-Hodgkin Lymphoma - Pipeline Review, H1 2015

Non-Hodgkin Lymphoma - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Non-Hodgkin Lymphoma - Pipeline Review, H1 2015’, provides an overview of the Non-Hodgkin Lymphoma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non-Hodgkin Lymphoma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non-Hodgkin Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non-Hodgkin Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non-Hodgkin Lymphoma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Non-Hodgkin Lymphoma Overview
Therapeutics Development
Non-Hodgkin Lymphoma – Therapeutics under Development by Companies
Non-Hodgkin Lymphoma – Therapeutics under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma – Pipeline Products Glance
Non-Hodgkin Lymphoma – Products under Development by Companies
Non-Hodgkin Lymphoma – Products under Investigation by Universities/Institutes
Non-Hodgkin Lymphoma – Companies Involved in Therapeutics Development
Non-Hodgkin Lymphoma – Therapeutics Assessment
Drug Profiles
Non-Hodgkin Lymphoma – Recent Pipeline Updates
Non-Hodgkin Lymphoma – Dormant Projects
Non-Hodgkin Lymphoma – Discontinued Products
Non-Hodgkin Lymphoma – Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2015
Number of Products under Development for Non-Hodgkin Lymphoma – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Number of Products under Development by Companies, H1 2015 (Contd..2)
Number of Products under Development by Companies, H1 2015 (Contd..3)
Number of Products under Development by Companies, H1 2015 (Contd..4)
Number of Products under Development by Companies, H1 2015 (Contd..5)
Number of Products under Development by Companies, H1 2015 (Contd..6)
Number of Products under Development by Companies, H1 2015 (Contd..7)
Number of Products under Development by Companies, H1 2015 (Contd..8)
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Development by Companies, H1 2015 (Contd..2)
Products under Development by Companies, H1 2015 (Contd..3)
Products under Development by Companies, H1 2015 (Contd..4)
Products under Development by Companies, H1 2015 (Contd..5)
Products under Development by Companies, H1 2015 (Contd..6)
Products under Development by Companies, H1 2015 (Contd..7)
Products under Development by Companies, H1 2015 (Contd..8)
Products under Development by Companies, H1 2015 (Contd..9)
Products under Development by Companies, H1 2015 (Contd..10)
Products under Development by Companies, H1 2015 (Contd..11)
Products under Development by Companies, H1 2015 (Contd..12)
Products under Development by Companies, H1 2015 (Contd..13)
Products under Development by Companies, H1 2015 (Contd..14)
Products under Development by Companies, H1 2015 (Contd..15)
Products under Investigation by Universities/Institutes, H1 2015
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1)
Non-Hodgkin Lymphoma – Pipeline by AB Science, H1 2015
Non-Hodgkin Lymphoma – Pipeline by AbbVie Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Actinium Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by ADC Therapeutics Sarl, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Affimed Therapeutics AG, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Agilvax, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Akron Molecules AG, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Allinky Biopharma, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Amgen Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Aptose Biosciences Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by arGEN-X BV, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Astellas Pharma Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by AstraZeneca Plc, H1 2015
Non-Hodgkin Lymphoma – Pipeline by AVEO Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Bayer AG, H1 2015
Non-Hodgkin Lymphoma – Pipeline by BioAtla, LLC, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Biogenomics Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by BioInvent International AB, H1 2015
Non-Hodgkin Lymphoma – Pipeline by BioMedics Japan Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Biothera, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Boehringer Ingelheim GmbH, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Boston Biomedical, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Bristol-Myers Squibb Company, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Calimmune, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Calithera Biosciences, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Celgene Corporation, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Cell Medica Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Celltrion, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Cellular Biomedicine Group, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Celon Pharma Sp. z o.o., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Chipscreen Biosciences Ltd, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Coherus BioSciences, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Conkwest, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Constellation Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Curis, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Dynavax Technologies Corporation, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Eisai Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Eli Lilly and Company, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Emergent BioSolutions Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by EpiZyme, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Formula Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Galderma S.A., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Gamida Cell Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Gilead Sciences, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Grupo Ferrer Internacional, S.A., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Hetero Drugs Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Hospira, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by iDD biotech SAS, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Immune Design Corp., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Immunomedics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Incyte Corporation, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Infinity Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Innate Pharma SA, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Innovent Biologics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Johnson & Johnson, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Juno Therapeutics Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Kainos Medicine, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Karyopharm Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Kite Pharma, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Komipharm International Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by MedImmune, LLC, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Merck & Co., Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Merck KGaA, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Mirna Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Mission Therapeutics Ltd, H1 2015
Non-Hodgkin Lymphoma – Pipeline by MorphoSys AG, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Mundipharma International Ltd, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Neopharm Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Neumedicines Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Nordic Nanovector ASA, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Novartis AG, H1 2015
Non-Hodgkin Lymphoma – Pipeline by NuCana BioMed Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Oncobiologics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by OncoSec Medical Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Onxeo SA, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Onyx Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Otsuka Holdings Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Oxford BioTherapeutics Ltd, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Panacea Biotec Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Pfizer Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Pharma Mar, S.A., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Pharmacyclics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Polaris Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by ProNAi Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Richter Gedeon Nyrt., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Sanofi, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Sareum Holdings Plc, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Seattle Genetics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Senhwa Biosciences, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Solasia Pharma K.K., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Soligenix, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Sorrento Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Stemline Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Supratek Pharma Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Taiwan Liposome Company, Ltd., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Tekmira Pharmaceuticals Corp., H1 2015
Non-Hodgkin Lymphoma – Pipeline by TetraLogic Pharmaceuticals, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Teva Pharmaceutical Industries Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by TG Therapeutics, Inc., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Theravectys S.A., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Transgene Biotek Limited, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Vivia Biotech, S.L., H1 2015
Non-Hodgkin Lymphoma – Pipeline by Xenetic Biosciences plc, H1 2015
Non-Hodgkin Lymphoma – Pipeline by Zymeworks Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Non-Hodgkin Lymphoma Therapeutics – Recent Pipeline Updates, H1 2015
Non-Hodgkin Lymphoma – Dormant Projects, H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..1), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..2), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..3), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..4), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..5), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..6), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..7), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..8), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..9), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..10), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..11), H1 2015
Non-Hodgkin Lymphoma – Dormant Projects (Contd..12), H1 2015
Non-Hodgkin Lymphoma – Discontinued Products, H1 2015
Non-Hodgkin Lymphoma – Discontinued Products (Contd..1), H1 2015
Non-Hodgkin Lymphoma – Discontinued Products (Contd..2), H1 2015
Non-Hodgkin Lymphoma – Discontinued Products (Contd..3), H1 2015
Non-Hodgkin Lymphoma – Discontinued Products (Contd..4), H1 2015
List of Figures
Number of Products under Development for Non-Hodgkin Lymphoma, H1 2015
Number of Products under Development for Non-Hodgkin Lymphoma – Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report